Patents Examined by Suzanne M. Noakes
  • Patent number: 11987829
    Abstract: The present invention relates to a recombinant microorganism which is modified to be capable of producing diosmin and hesperidin and to the use thereof for producing diosmin and/or hesperidin.
    Type: Grant
    Filed: February 11, 2020
    Date of Patent: May 21, 2024
    Assignee: LES LABORATOIRES SERVIER
    Inventors: Cyrille Pauthenier, André Le Jeune, Hélène Scornec, Célia Roussel, Laetitia Joubert
  • Patent number: 11987791
    Abstract: The present invention provides agents and compositions for modulating expression (e.g., enhanced or reduced expression) of a hepatocyte nuclear factor 4 alpha (HNF4?) gene by targeting an HNF4? expression control region and methods of use thereof for treating an HNF4? associated disorder, e.g., cirrhosis.
    Type: Grant
    Filed: September 23, 2020
    Date of Patent: May 21, 2024
    Assignee: Omega Therapeutics, Inc.
    Inventors: Jesse Jerome Smith, Jodi Michelle Kennedy, Jeremiah D. Farelli, Kendrick Alan Goss, Adam Walter Scheidegger, Yoseph Kassa, Christian Wessel Cobaugh, Timsi Rao
  • Patent number: 11987637
    Abstract: The invention concerns methods for preventing the reduction of disulfide bonds during the recombinant production of disulfide-containing polypeptides. In particular, the invention concerns the prevention of disulfide bond reduction during harvesting of disulfide-containing polypeptides, including antibodies, from recombinant host cell cultures.
    Type: Grant
    Filed: January 11, 2024
    Date of Patent: May 21, 2024
    Assignee: Genentech, Inc.
    Inventors: Yung-Hsiang Kao, Michael W. Laird, Melody Trexler Schmidt, Rita L. Wong, Daniel P. Hewitt
  • Patent number: 11981899
    Abstract: The invention relates to, in part, improved methods for the production of beta-lactamase using Escherichia coli (E. coli) cells. High yield production of beta-lactamase is achieved using methods of the invention.
    Type: Grant
    Filed: December 1, 2022
    Date of Patent: May 14, 2024
    Assignee: Theriva Biologics, Inc.
    Inventors: Andrew Bristol, Michael Kaleko, Steven Hubert
  • Patent number: 11976266
    Abstract: The present strains and methods of the disclosure relate to genetic modifications in filamentous fungi that give rise to variant strains having altered phenotypes, altered morphologies, altered growth characteristics, and the like. More specifically, as presented and described herein, such variant strains of filamentous fungi comprising reduced viscosity phenotypes are well-suited for growth in submerged cultures (e.g., for the large-scale production of enzymes and other proteins or metabolites for commercial applications).
    Type: Grant
    Filed: April 16, 2019
    Date of Patent: May 7, 2024
    Assignee: DANISCO US INC.
    Inventors: Elizabeth A. Bodie, Robert James Pratt, II, Michael Ward, Jonathan M. Palmer
  • Patent number: 11976127
    Abstract: The invention concerns methods and means for preventing the reduction of disulfide bonds during the recombinant production of disulfide-containing polypeptides. In particular, the invention concerns the prevention of disulfide bond reduction during harvesting of disulfide-containing polypeptides, including antibodies, from recombinant host cell cultures.
    Type: Grant
    Filed: April 20, 2023
    Date of Patent: May 7, 2024
    Assignee: Genentech, Inc.
    Inventors: Yung-Hsiang Kao, Michael W. Laird, Melody Trexler Schmidt, Rita L. Wong, Daniel P. Hewitt
  • Patent number: 11970730
    Abstract: The present disclosure describes compositions of matter comprising a ribonucleoprotein complex comprising a nucleic acid-guided nuclease and a guide RNA, and further comprising and a blocking nucleic acid molecule represented by Formula III in the 5?-to-3? direction comprises: T-D-M-A-(B-L)J-C; wherein T is 17-135 nucleotides in length; D is 0-10 nucleotides in length; M is 1-25 nucleotides in length or is absent, wherein if M is absent then T-D and A-(B-L)J-C are separate nucleic acid strands; A is 0-15 nucleotides in length and comprises at least 50% sequence complementarity to D; B is 4-12 nucleotides in length and comprises at least 50% sequence complementarity to T; L is 3-25 nucleotides in length; J is an integer between 1 and 10; C is 4-15 nucleotides in length; and wherein the blocking nucleic acid molecule comprises a sequence complementary to a gRNA.
    Type: Grant
    Filed: June 10, 2023
    Date of Patent: April 30, 2024
    Assignee: VedaBio, Inc.
    Inventors: Anurup Ganguli, Ariana Mostafa, Jacob Berger, Ashish Pandey, Rashid Bashir
  • Patent number: 11965186
    Abstract: The present disclosure provides engineered nucleic acid-guided nickases and optimized scaffolds for making rational, direct edits to nucleic acids in live cells.
    Type: Grant
    Filed: February 20, 2022
    Date of Patent: April 23, 2024
    Assignee: Inscripta, Inc.
    Inventors: Juhan Kim, Benjamin Mijts
  • Patent number: 11959111
    Abstract: The present invention relates to cleaning compositions comprising polypeptides having peptidoglycan degradation activity, as well as use of the cleaning compositions for cleaning of an item such as a textile or a surface.
    Type: Grant
    Filed: December 19, 2019
    Date of Patent: April 16, 2024
    Assignee: Novozymes A/S
    Inventors: Christian Berg Oehlenschlaeger, Dorotea Raventos Segura, Jesper Salomon, Fabian Barrientos Garcia, Lillian Eva Tang Baltsen, Christian Bech Rosen
  • Patent number: 11959124
    Abstract: Disclosed are methods and systems for the analysis activity of enzyme disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13 (ADAMTS13) in a sample. The methods and systems disclosed herein can be useful for diagnosis of thrombotic thrombocytopenic purpura in a patient.
    Type: Grant
    Filed: November 4, 2020
    Date of Patent: April 16, 2024
    Assignee: Laboratory Corporation of America Holdings
    Inventors: Russell Philip Grant, Christopher Michael Shuford, Meghan Norris Bradley
  • Patent number: 11959123
    Abstract: The present invention aims to provide a novel method that can quantify diaminopimelic acid-containing bacteria in a test sample. The present invention relates to a method of quantifying diaminopimelic acid-containing bacteria in a test sample, including a step of quantifying the diaminopimelic acid-containing bacteria, using, as an index, the amount of diaminopimelic acid derived from the diaminopimelic acid-containing bacteria in the test sample.
    Type: Grant
    Filed: March 9, 2020
    Date of Patent: April 16, 2024
    Assignee: SUNTORY HOLDINGS LIMITED
    Inventors: Yosuke Sato, Naoki Kasajima, Toshihiko Fukuda, Masayuki Ida
  • Patent number: 11959108
    Abstract: The present invention provides engineered protease polypeptides and compositions thereof. The engineered protease polypeptides have been optimized to provide improved activity, improved thermostability, protease stability, autolytic stability, and stability under a range of pH conditions, including acidic (pH<7) and basic (pH>7) conditions. The invention also relates to the use of the compositions comprising the engineered protease polypeptides for therapeutic and/or nutritional purposes. The present invention also provides polynucleotides encoding the engineered protease polypeptides, as well as methods for making the engineered polynucleotides and protease polypeptides.
    Type: Grant
    Filed: August 27, 2021
    Date of Patent: April 16, 2024
    Assignees: Codexis, Inc., Societe des Produits Nestle S.A.
    Inventors: Chinping Chng, Nikki Dellas, Ravi David Garcia, Moulay Hicham Alaoui Ismaili, Kristen Jean Vallieu, Kerryn McCluskie
  • Patent number: 11952604
    Abstract: Provided is a method for preparing Rebaudioside J using an enzymatic method, comprising using rebaudioside A as a substrate, and making the substrate, in the presence of a glycosyl donor, react under the catalysis of a UDP-glycosyltransferase-containing recombinant cell and/or UDP-glycosyltransferase prepared therefrom to generate Rebaudioside J.
    Type: Grant
    Filed: June 6, 2022
    Date of Patent: April 9, 2024
    Assignee: PepsiCo, Inc.
    Inventors: Alex Tao, Guoqing Li, Wenxia Wang, Leilei Zheng, Chunlei Zhu, Xiaoliang Liang, Kuikiu Chan
  • Patent number: 11952557
    Abstract: The present invention relates to alpha-amylase variants. The present invention also relates to polynucleotides encoding the variants; nucleic acid constructs, vectors, and host cells comprising the polynucleotides; and methods of using the variants.
    Type: Grant
    Filed: March 23, 2022
    Date of Patent: April 9, 2024
    Assignee: Novozymes A/S
    Inventors: Carsten Andersen, Chakshusmathi Ghadiyaram, Rajendra Kulothungan Sainathan, Padmavathi Balumuri, Padma Venkatachalam Iyer, Iben Damager, Astrid Munch, Sohel Dalal
  • Patent number: 11951231
    Abstract: A therapeutic agent for intervertebral disc degeneration that contains LASCol obtained by enzymatically cleaving a terminus of collagen.
    Type: Grant
    Filed: January 31, 2019
    Date of Patent: April 9, 2024
    Assignee: KINKI UNIVERSITY
    Inventors: Takashi Yurube, Yoshiki Takeoka, Koichi Morimoto, Saori Kunii, Kaoru Omae
  • Patent number: 11945853
    Abstract: Provided herein are polynucleic acids and expression vectors for the expression and secretion of angiotensin peptide fragments (e.g., angiotensin-(1-7)) in probiotic bacteria. Provided herein are also probiotic compositions that enable efficient, cost-effective and patient friendly oral therapeutics for treating diverse pathological conditions that involve the renin-angiotensin system (RAS), e.g., pulmonary hypertension, diabetes, diabetic complications, cardiovascular diseases, and ocular inflammatory and neurodegenerative diseases.
    Type: Grant
    Filed: June 14, 2022
    Date of Patent: April 2, 2024
    Assignee: UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED
    Inventors: Qiuhong Li, Mohan Raizada
  • Patent number: 11939584
    Abstract: Genetically modified microorganisms that have the ability to convert carbon substrates into chemical products such as 2,3-BDO are disclosed. For example, genetically modified methanotrophs that are capable of generating 2,3-BDO at high titers from a methane source are disclosed. Methods of making these genetically modified microorganisms and methods of using them are also disclosed.
    Type: Grant
    Filed: July 31, 2021
    Date of Patent: March 26, 2024
    Assignee: PRECIGEN, INC.
    Inventors: Xinhua Zhao, Mark Anton Held, Tina Huynh, Lily Yuin Chao, Na Trinh, Matthias Helmut Schmalisch, Bryan Yeh, James Kealey, Kevin Lee Dietzel
  • Patent number: 11938157
    Abstract: Provided is Lactobacillus paracasei TCI727, deposited in the Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH (DSMZ) with a deposit number of DSM 33756. A method for improving calcium absorption of a subject in need thereof by using the Lactobacillus paracasei TCI727 or metabolites thereof is also provided. The method includes administering to the subject an effective amount of a composition comprising the Lactobacillus paracasei TCI727 or the metabolites thereof.
    Type: Grant
    Filed: July 13, 2022
    Date of Patent: March 26, 2024
    Assignee: TCI CO., LTD.
    Inventors: Yung-Hsiang Lin, Chu-Han Huang
  • Patent number: 11939605
    Abstract: Thermostable Cas9 nucleases. The present invention relates to the field of genetic engineering and more particularly to nucleic acid editing and genome modification. The present invention provides an isolated Cas protein or polypeptide fragment thereof having an amino acid sequence of SEQ ID NO: 1 or a sequence of at least 77% identity therewith. The Cas protein or polypeptide is capable of binding, cleaving, marking or modifying a double stranded target polynucleotide at a temperature in the range 20° C. and 100° C. inclusive. The invention further provides isolated nucleic acid molecules encoding the Cas9 nucleases, expression vectors and host cells. The invention also provides PAM sequences recognized by the Cas protein or polypeptide, The Cas9 nucleases disclosed herein provide novel tools for genetic engineering in general, in particular at elevated temperatures and are of particular value in the genetic manipulation of thermophilic organisms; particularly microorganisms.
    Type: Grant
    Filed: January 14, 2022
    Date of Patent: March 26, 2024
    Assignees: Wageningen Universiteit, Stichting Voor De Technische Wetenschappen
    Inventors: John Van Der Oost, Richard Van Kranenburg, Elleke Fenna Bosma, Ioannis Mougiakos, Prarthana Mohanraju
  • Patent number: 11932869
    Abstract: The present invention disclose a method for digesting RPE cells to dissociate adherent cells, comprising steps: (1) using 1× recombinant enzyme TrypLE to cover RpE cells evenly; (2) using neutral protease Dispase II solution to cover RPE cells evenly, in which steps (1) and (2) are applied step by step.
    Type: Grant
    Filed: February 20, 2019
    Date of Patent: March 19, 2024
    Assignee: EYECURE THERAPEUTICS, INC. (JIANGSU)
    Inventors: Zhanhai Yan, Lei Xie